Production (Stage)
SpringWorks Therapeutics, Inc.
SWTX
$46.48
$0.210.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 133.68% | 1,029.96% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 133.68% | 1,029.96% | -- | -- | -- |
| Cost of Revenue | 193.43% | 1,216.11% | -- | -- | -- |
| Gross Profit | 130.05% | 1,014.33% | -- | -- | -- |
| SG&A Expenses | 27.26% | 28.85% | 32.34% | 23.08% | 36.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.78% | 37.51% | 27.67% | 26.31% | 47.93% |
| Operating Income | 14.26% | 17.39% | 31.03% | 45.78% | -20.89% |
| Income Before Tax | 4.80% | 18.05% | 32.61% | 48.77% | -19.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.80% | 18.05% | 32.61% | 48.77% | -19.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.80% | 18.05% | 32.61% | 48.77% | -19.02% |
| EBIT | 14.26% | 17.39% | 31.03% | 45.78% | -20.89% |
| EBITDA | 14.77% | 17.97% | 31.67% | 46.55% | -20.34% |
| EPS Basic | 6.22% | 28.01% | 43.27% | 56.83% | -0.56% |
| Normalized Basic EPS | 6.23% | 28.01% | 43.27% | 56.83% | -0.57% |
| EPS Diluted | 6.22% | 28.01% | 43.27% | 56.83% | -0.56% |
| Normalized Diluted EPS | 6.23% | 28.01% | 43.27% | 56.83% | -0.57% |
| Average Basic Shares Outstanding | 1.51% | 13.83% | 18.78% | 18.66% | 18.36% |
| Average Diluted Shares Outstanding | 1.51% | 13.83% | 18.78% | 18.66% | 18.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |